Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haioun, C.
Right arrow Articles by Reyes, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haioun, C.
Right arrow Articles by Reyes, F.
Journal of Clinical Oncology, Vol 18, Issue 16 (August), 2000: 3025-3030
© 2000 American Society for Clinical Oncology

Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte Study

By Corinne Haioun, Eric Lepage, Christian Gisselbrecht, Gilles Salles, Bertrand Coiffier, Pauline Brice, André Bosly, Pierre Morel, Christiane Nouvel, Hervé Tilly, Pierre Lederlin, Catherine Sebban, Josette Brière, Philippe Gaulard, Félix Reyes

From the Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil; Hôpital Saint-Louis, AP-HP, Paris; Centre Hospitalier Lyon-Sud, Pierre Bénite; Centre Henri Becquerel, Rouen; Centre Hospitalier Huriez, Lille; Hôpital Purpan, Toulouse; Hôpitaux de Brabois, Nancy; Centre Léon Bérard, Lyon, France; and Cliniques Universitaires de Mont Godinne, Yvoir, Belgium.

Address reprint requests to Corinne Haioun, MD, Service d’Hématologie Clinique, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France; email corinne .haioun{at}hmn.ap-hop-paris.fr

PURPOSE: To present the final analysis, with a median follow-up of 8 years, of the LNH87–2 randomized study, which compares consolidative sequential chemotherapy (ifosfamide plus etoposide, asparaginase, and cytarabine) with high-dose therapy (HDT) using cyclophosphamide, carmustine, and etoposide (CBV regimen) followed by stem-cell transplantation in patients with aggressive non-Hodgkin’s lymphoma in first complete remission after induction, focusing on high/intermediate- and high-risk patients identified by the age-adjusted international prognostic index.

PATIENTS AND METHODS: Among the 916 eligible patients, 451 presented with two (n = 318) or three (n = 133) risk factors. After reaching complete remission to induction therapy, 236 of these higher risk patients were assessable for the consolidation phase, with 125 patients in the HDT arm and 111 in the sequential chemotherapy arm.

RESULTS: Among these 451 higher risk patients, 277 (61%) achieved complete remission after induction treatment. In the population of 236 randomized patients, HDT was superior to sequential chemotherapy, with 8-year disease-free survival rates of 55% (95% confidence interval [CI], 46% to 64%) and 39% (95% CI, 30% to 48%), respectively (P = .02; relative risk, 1.56). The 8-year survival rate was significantly superior in the HDT arm (64%; 95% CI, 55% to 73%) compared with the sequential chemotherapy arm (49%; 95% CI, 39% to 59%) (P = .04; relative risk, 1.51).

CONCLUSION: On the basis of the final analysis of this prospectively treated series of patients, retrospectively analyzed on the basis of the International Prognostic Index, we hypothesize that HDT benefits patients at higher risk who achieve complete remission after induction treatment.




This article has been cited by other articles:


Home page
 JCOHome page
C. Tarella, M. Zanni, M. Magni, F. Benedetti, C. Patti, T. Barbui, A. Pileri, M. Boccadoro, F. Ciceri, A. Gallamini, et al.
Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey
J. Clin. Oncol., July 1, 2008; 26(19): 3166 - 3175.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mourad, N. Mounier, J. Briere, E. Raffoux, A. Delmer, A. Feller, C. J. L. M. Meijer, J.-F. Emile, R. Bouabdallah, A. Bosly, et al.
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood, May 1, 2008; 111(9): 4463 - 4470.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Kyriakou, C. Canals, A. Goldstone, D. Caballero, B. Metzner, G. Kobbe, H.-J. Kolb, J. Kienast, P. Reimer, J. Finke, et al.
High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
J. Clin. Oncol., January 10, 2008; 26(2): 218 - 224.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
N. Schmitz, P. Dreger, B. Glass, and A. Sureda
Allogeneic transplantation in lymphoma: current status
Haematologica, November 1, 2007; 92(11): 1533 - 1548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Oyama, K. Yamamoto, N. Asano, A. Oshiro, R. Suzuki, Y. Kagami, Y. Morishima, K. Takeuchi, T. Izumo, S. Mori, et al.
Age-Related EBV-Associated B-Cell Lymphoproliferative Disorders Constitute a Distinct Clinicopathologic Group: A Study of 96 Patients
Clin. Cancer Res., September 1, 2007; 13(17): 5124 - 5132.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. O. Armitage
How I treat patients with diffuse large B-cell lymphoma
Blood, July 1, 2007; 110(1): 29 - 36.
[Full Text] [PDF]

Home page
 haematolHome page
J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al.
Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma
Haematologica, June 1, 2007; 92(6): 778 - 783.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Thieblemont and B. Coiffier
Lymphoma in Older Patients
J. Clin. Oncol., May 10, 2007; 25(14): 1916 - 1923.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff
Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy
Ann. Onc., May 1, 2007; 18(5): 931 - 939.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. F. Verdonck, A. Notenboom, D. D. de Jong, M. A. MacKenzie, G. E. G. Verhoef, M. H. H. Kramer, G. J. Ossenkoppele, J. K. Doorduijn, P. Sonneveld, and G. W. van Imhoff
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)
Blood, April 1, 2007; 109(7): 2759 - 2766.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Bossard, K. Belhadj, F. Reyes, N. Martin-Garcia, F. Berger, J. A. Kummer, J. Briere, A.-C. Baglin, S. Cheze, J. Bosq, et al.
Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
Blood, March 1, 2007; 109(5): 2183 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
M. Witzens-Harig, C. Heilmann, M. Hensel, M. Kornacker, A. Benner, R. Haas, S. Fruehauf, and A. D. Ho
Long-Term Follow-Up of Patients with Non-Hodgkin Lymphoma Following Myeloablative Therapy and Autologous Transplantation of CD34+-Selected Peripheral Blood Progenitor Cells
Stem Cells, January 1, 2007; 25(1): 228 - 235.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Dupuis, J.-F. Emile, N. Mounier, C. Gisselbrecht, N. Martin-Garcia, T. Petrella, R. Bouabdallah, F. Berger, A. Delmer, B. Coiffier, et al.
Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study
Blood, December 15, 2006; 108(13): 4163 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Betticher, G Martinelli, J. Radford, M Kaufmann, M. Dyer, U Kaiser, W. Aulitzky, J Beck, A von Rohr, T Kovascovics, et al.
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL)
Ann. Onc., October 1, 2006; 17(10): 1546 - 1552.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Habermann, E. A. Weller, V. A. Morrison, R. D. Gascoyne, P. A. Cassileth, J. B. Cohn, S. R. Dakhil, B. Woda, R. I. Fisher, B. A. Peterson, et al.
Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma
J. Clin. Oncol., July 1, 2006; 24(19): 3121 - 3127.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Glass, M. Kloess, M. Bentz, G. Schlimok, W. E. Berdel, A. Feller, L. Trumper, M. Loeffler, M. Pfreundschuh, N. Schmitz, et al.
Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma
Blood, April 15, 2006; 107(8): 3058 - 3064.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Olivieri, G. Santini, C. Patti, T. Chisesi, C. De Souza, A. Rubagotti, S. Aversa, A. Billio, A. Porcellini, M. Candela, et al.
Upfront high-dose sequential therapy (HDS) versus VACOP-B with or without HDS in aggressive non-Hodgkin's lymphoma: long-term results by the NHLCSG
Ann. Onc., December 1, 2005; 16(12): 1941 - 1948.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S.-T. Lim, R. Karim, A. Tulpule, B. N. Nathwani, and A. M. Levine
Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy
J. Clin. Oncol., November 20, 2005; 23(33): 8477 - 8482.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Coiffier
State-of-the-Art Therapeutics: Diffuse Large B-Cell Lymphoma
J. Clin. Oncol., September 10, 2005; 23(26): 6387 - 6393.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. A. Gregory and L. Trumper
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
Ann. Onc., September 1, 2005; 16(9): 1413 - 1424.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. S. Abramson and M. A. Shipp
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Blood, August 15, 2005; 106(4): 1164 - 1174.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Josting, M. Sieniawski, J.-P. Glossmann, O. Staak, L. Nogova, N. Peters, M. Mapara, B. Dorken, Y. Ko, B. Metzner, et al.
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
Ann. Onc., August 1, 2005; 16(8): 1359 - 1365.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Ferme, B. Christian, E. Lepage, H. Tilly, F. Morschhauser, et al.
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol., June 20, 2005; 23(18): 4117 - 4126.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. W. van Imhoff, B. van der Holt, M. A. MacKenzie, M. B. van't Veer, P. W. Wijermans, G. J. Ossenkoppele, H. C. Schouten, P. Sonneveld, M. M.C. Steijaert, P. M. Kluin, et al.
Impact of Three Courses of Intensified CHOP Prior to High-Dose Sequential Therapy Followed by Autologous Stem-Cell Transplantation As First-Line Treatment in Poor-Risk, Aggressive Non-Hodgkin's Lymphoma: Comparative Analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40
J. Clin. Oncol., June 1, 2005; 23(16): 3793 - 3801.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al.
All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., December 1, 2004; 15(12): 1790 - 1797.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al.
Prognostic Factors in Patients With Aggressive Non-Hodgkin's Lymphoma Treated by Front-Line Autotransplantation After Complete Remission: A Cohort Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol., July 15, 2004; 22(14): 2826 - 2834.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P. Escalon, R. E. Champlin, R. M. Saliba, S. A. Acholonu, C. Hosing, L. Fayad, S. Giralt, N. T. Ueno, F. Maadani, B. Pro, et al.
Nonmyeloablative Allogeneic Hematopoietic Transplantation: A Promising Salvage Therapy for Patients With Non-Hodgkin's Lymphoma Whose Disease Has Failed a Prior Autologous Transplantation
J. Clin. Oncol., June 15, 2004; 22(12): 2419 - 2423.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Bendandi, S. A. Pileri, and P. L. Zinzani
Challenging paradigms in lymphoma treatment
Ann. Onc., May 1, 2004; 15(5): 703 - 711.
[Full Text] [PDF]

Home page
 NEJMHome page
N. Milpied, E. Deconinck, F. Gaillard, V. Delwail, C. Foussard, C. Berthou, R. Gressin, V. Lucas, P. Colombat, J.-L. Harousseau, et al.
Initial Treatment of Aggressive Lymphoma with High-Dose Chemotherapy and Autologous Stem-Cell Support
N. Engl. J. Med., March 25, 2004; 350(13): 1287 - 1295.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Belhadj, M.-H. Delfau-Larue, T. Elgnaoui, F. Beaujean, J.-L. Beaumont, C. Pautas, I. Gaillard, Y. Kirova, A. Allain, P. Gaulard, et al.
Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study
Ann. Onc., March 1, 2004; 15(3): 504 - 510.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Andre, N. Mounier, X. Leleu, A. Sonet, P. Brice, M. Henry-Amar, H. Tilly, B. Coiffier, A. Bosly, P. Morel, et al.
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients
Blood, February 15, 2004; 103(4): 1222 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Tilly, E. Lepage, B. Coiffier, M. Blanc, R. Herbrecht, A. Bosly, M. Attal, G. Fillet, C. Guettier, T. J. Molina, et al.
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma
Blood, December 15, 2003; 102(13): 4284 - 4289.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Binn, A. Ruskone-Fourmestraux, E. Lepage, C. Haioun, A. Delmer, P. Aegerter, A. Lavergne, C. Guettier, and J.-C. Delchier
Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat diffuse large B-cell gastric lymphoma
Ann. Onc., December 1, 2003; 14(12): 1751 - 1757.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. E. Abrey, C. H. Moskowitz, W. P. Mason, M. Crump, D. Stewart, P. Forsyth, N. Paleologos, D. D. Correa, N. D. Anderson, D. Caron, et al.
Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis
J. Clin. Oncol., November 15, 2003; 21(22): 4151 - 4156.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. G. Laport, B. L. Levine, E. A. Stadtmauer, S. J. Schuster, S. M. Luger, S. Grupp, N. Bunin, F. J. Strobl, J. Cotte, Z. Zheng, et al.
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
Blood, September 15, 2003; 102(6): 2004 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
G. J. Elfenbein
Stem-Cell Transplantation for High-Risk Breast Cancer
N. Engl. J. Med., July 3, 2003; 349(1): 80 - 82.
[Full Text] [PDF]

Home page
 JCOHome page
B. Coiffier
Increasing Chemotherapy Intensity in Aggressive Lymphomas: A Renewal?
J. Clin. Oncol., July 1, 2003; 21(13): 2457 - 2459.
[Full Text] [PDF]

Home page
 JCOHome page
D. W. Blayney, M. L. LeBlanc, T. Grogan, E. R. Gaynor, R. A. Chapman, C. H. Spiridonidis, S. A. Taylor, S. I. Bearman, T. P. Miller, and R. I. Fisher
Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349)
J. Clin. Oncol., July 1, 2003; 21(13): 2466 - 2473.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Mounier, J. Briere, C. Gisselbrecht, J.-F. Emile, P. Lederlin, C. Sebban, F. Berger, A. Bosly, P. Morel, H. Tilly, et al.
Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
Blood, June 1, 2003; 101(11): 4279 - 4284.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Martelli, F. Gherlinzoni, A. De Renzo, P. L. Zinzani, A. De Vivo, M. Cantonetti, B. Falini, S. Storti, G. Meloni, M. Rizzo, et al.
Early Autologous Stem-Cell Transplantation Versus Conventional Chemotherapy as Front-Line Therapy in High-Risk, Aggressive Non-Hodgkin's Lymphoma: An Italian Multicenter Randomized Trial
J. Clin. Oncol., April 1, 2003; 21(7): 1255 - 1262.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Takeyama, M. Ogura, Y. Morishima, M. Kasai, Y. Kiyama, K. Ohnishi, H. Mitsuya, F. Kawano, Y. Masaki, T. Sasaki, et al.
A Dose-finding Study of Glycosylated G-CSF (Lenograstim) Combined with CHOP Therapy for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma
Jpn. J. Clin. Oncol., February 1, 2003; 33(2): 78 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Limat, K. Demesmay, L. Voillat, Y. Bernard, E. Deconinck, A. Brion, A. Sabbah, M. C. Woronoff-Lemsi, and J. Y. Cahn
Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
Ann. Onc., February 1, 2003; 14(2): 277 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. D. Caballero, J. A. Perez-Simon, A. Iriondo, J. J. Lahuerta, J. Sierra, J. Marin, M. Gandarillas, R. Arranz, J. Zuazu, V. Rubio, et al.
High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group
Ann. Onc., January 1, 2003; 14(1): 140 - 151.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. I. Fisher
Autologous Stem-Cell Transplantation as a Component of Initial Treatment for Poor-Risk Patients With Aggressive Non-Hodgkin's Lymphoma: Resolved Issues Versus Remaining Opportunity
J. Clin. Oncol., November 15, 2002; 20(22): 4411 - 4412.
[Full Text] [PDF]

Home page
 JCOHome page
U. Kaiser, I. Uebelacker, U. Abel, J. Birkmann, L. Trumper, H. Schmalenberg, T. Karakas, B. Metzner, D. K. Hossfeld, H. G. Bischoff, et al.
Randomized Study to Evaluate the Use of High-Dose Therapy as Part of Primary Treatment for "Aggressive" Lymphoma
J. Clin. Oncol., November 15, 2002; 20(22): 4413 - 4419.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Itoh, T. Ohtsu, H. Fukuda, Y. Sasaki, M. Ogura, Y. Morishima, T. Chou, K. Aikawa, N. Uike, F. Mizorogi, et al.
Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505
Ann. Onc., September 1, 2002; 13(9): 1347 - 1355.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Brice, C. Haioun, M. Andre, and C. Gisselbrecht
Pregnancies after high-dose chemotherapy and autologous stem cell transplantation in aggressive lymphomas
Blood, June 28, 2002; 100(2): 736 - 736.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. W. Otieno, C. Banura, E. Katongole-Mbidde, J. L. Johnson, M. Ghannoum, A. Dowlati, R. Renne, E. Arts, C. Whalen, M. M. Lederman, et al.
Therapeutic Challenges of AIDS-Related Non-Hodgkin's Lymphoma in the United States and East Africa
J Natl Cancer Inst, May 15, 2002; 94(10): 718 - 732.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gisselbrecht, E. Lepage, T. Molina, B. Quesnel, G. Fillet, P. Lederlin, B. Coiffier, H. Tilly, J. Gabarre, F. Guilmin, et al.
Shortened First-Line High-Dose Chemotherapy for Patients With Poor-Prognosis Aggressive Lymphoma
J. Clin. Oncol., May 15, 2002; 20(10): 2472 - 2479.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Vose, G. Sharp, W. C. Chan, C. Nichols, K. Loh, D. Inwards, R. Rifkin, P. J. Bierman, J. C. Lynch, D. D. Weisenburger, et al.
Autologous Transplantation for Aggressive Non-Hodgkin's Lymphoma: Results of a Randomized Trial Evaluating Graft Source and Minimal Residual Disease
J. Clin. Oncol., May 1, 2002; 20(9): 2344 - 2352.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Mounier, D. Simon, C. Haioun, P. Gaulard, C. Gisselbrecht, and I. Khouri
Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas
J. Clin. Oncol., March 1, 2002; 20(5): 1426 - 1427.
[Full Text] [PDF]

Home page
 NEJMHome page
B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly, R. Bouabdallah, P. Morel, E. Van Den Neste, G. Salles, P. Gaulard, et al.
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
N. Engl. J. Med., January 24, 2002; 346(4): 235 - 242.
[Abstract] [Full Text] [PDF]